Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00087113 · ClinicalTrials.gov registry record · Phase 2
Pemetrexed Disodium in Treating Patients With Recurrent Cancer of the Cervix
A Phase 2 study of Cervical Cancer, sponsored by Gynecologic Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Study locations
NCT00087113: Completed Phase 2 study of Cervical Cancer, sponsored by Gynecologic Oncology Group.
NCT00087113 is a Phase 2 study of Cervical Cancer that has completed, run by Gynecologic Oncology Group. The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00087113, a Phase 2 study of Cervical Cancer, has completed, sponsored by Gynecologic Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy, such as pemetrexed disodium, work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase II trial is studying how well pemetrexed disodium works in treating patients with recurrent cancer of the cervix.
Conditions Studied
Interventions
- DRUG pemetrexed disodium
Study Locations (20)
Ohio
- Case Comprehensive Cancer Center - Cleveland
- MetroHealth's Cancer Care Center at MetroHealth Medical Center - Cleveland
- Hillcrest Cancer Center at Hillcrest Hospital - Mayfield Heights
Missouri
- CCOP - Kansas City - Kansas City
- St. John's Regional Health Center - Springfield
New York
- SUNY Downstate Medical Center - Brooklyn
- SUNY Upstate Medical University Hospital - Syracuse
North Carolina
- Hope A Women's Cancer Center - Asheville
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill - Chapel Hill
Oklahoma
- Oklahoma University Medical Center - Oklahoma City
- Cancer Care Associates - Midtown Tulsa - Tulsa
Pennsylvania
- Rosenfeld Cancer Center at Abington Memorial Hospital - Abington
- Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest - Allentown
Arkansas
- Arkansas Cancer Research Center at University of Arkansas for Medical Sciences - Little Rock
California
- Doctors Medical Center - Modesto
Trial Details
| Field | Value |
|---|---|
| Start Date | 2004-08 |
| Phase | Phase 2 |
What the finished NCT00087113 record still lists
NCT00087113 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 1 condition, with Cervical Cancer appearing as the primary indexed condition, and to 1 intervention - of which pemetrexed disodium is the first listed.
NCT00087113 names 20 study sites across 13 states, led by Ohio, Missouri, New York.
Frequently Asked Questions
What is clinical trial NCT00087113 about?
NCT00087113 is a clinical study titled "Pemetrexed Disodium in Treating Patients With Recurrent Cancer of the Cervix". RATIONALE: Drugs used in chemotherapy, such as pemetrexed disodium, work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase II trial is studying how well pemetrexed disodium works in treating patients with recurrent cancer of the cervix.
What is the current status of trial NCT00087113?
This trial is currently completed. It is a Phase 2 study. The study started on 2004-08.
What conditions does trial NCT00087113 study?
This clinical trial studies the following conditions: Cervical Cancer.
What interventions are being tested in trial NCT00087113?
The interventions under investigation include: pemetrexed disodium (DRUG).
Who is sponsoring clinical trial NCT00087113?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00087113 being conducted?
This trial has 20 study locations across Arkansas, California, Connecticut, Illinois, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cervical Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
RECRUITING · Phase 2
-
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 2
-
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
RECRUITING · Phase 2
-
Pembrolizumab and Lenvatinib in Advanced Cervical Cancer
RECRUITING · Phase 2
-
A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer
RECRUITING · Phase 2
-
Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia